Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2022 Jul 19;17(7):e0271614. doi: 10.1371/journal.pone.0271614

Developmental exposure to the brominated flame retardant DE-71 reduces serum thyroid hormones in rats without hypothalamic-pituitary-thyroid axis activation or neurobehavioral changes in offspring

Louise Ramhøj 1,*, Terje Svingen 1, Karen Mandrup 1, Ulla Hass 1, Søren Peter Lund 2, Anne Marie Vinggaard 1, Karin Sørig Hougaard 2,3, Marta Axelstad 1
Editor: Jamie C DeWitt4
PMCID: PMC9295973  PMID: 35853081

Abstract

Polybrominated diphenyl ethers (PBDEs) are legacy flame retardants for which human exposure remains ubiquitous. This is of concern since these chemicals can perturb development and cause adverse health effects. For instance, DE-71, a technical mixture of PBDEs, can induce liver toxicity as well as reproductive and developmental toxicity. DE-71 can also disrupt the thyroid hormone (TH) system which may induce developmental neurotoxicity indirectly. However, in developmental toxicity studies, it remains unclear how DE-71 exposure affects the offspring’s thyroid hormone system and if this dose-dependently relates to neurodevelopmental effects. To address this, we performed a rat toxicity study by exposing pregnant dams to DE-71 at 0, 40 or 60 mg/kg/day during perinatal development from gestational day 7 to postnatal day 16. We assessed the TH system in both dams and their offspring, as well as potential hearing and neurodevelopmental effects in prepubertal and adult offspring. DE-71 significantly reduced serum T4 and T3 levels in both dams and offspring without a concomitant upregulation of TSH, thus inducing a hypothyroxinemia-like effect. No discernible effects were observed on the offspring’s brain function when assessed in motor activity boxes and in the Morris water maze, or on offspring hearing function. Our results, together with a thorough review of the literature, suggest that DE-71 does not elicit a clear dose-dependent relationship between low serum thyroxine (T4) and effects on the rat brain in standard behavioral assays. However, low serum TH levels are in themselves believed to be detrimental to human brain development, thus we propose that we lack assays to identify developmental neurotoxicity caused by chemicals disrupting the TH system through various mechanisms.

Introduction

Disrupted thyroid hormone (TH) signaling during perinatal life can adversely affect the developing brain. This is because proper brain development is critically dependent on spatiotemporally controlled thyroid hormone action [1, 2]. The TH system, however, comprise an intricate network of interconnected organs and signaling events. Thus, TH system disruption by chemical substances can occur by different mechanisms. This includes inhibition of thyroperoxidase (TPO), the sodium/iodide symporter (NIS), deiodinases, dehalogenases, and transporters such as the monocarboxylate transporter 8 (MCT8). It can also occur by displacement of TH from the serum distributor protein transthyretin (TTR) or augmentation of liver metabolism and excretion of TH through induction of metabolizing enzymes and excretion-transporters [1, 3, 4].

Exposure to compounds targeting any of the abovementioned TH system components can have different effects on the TH system itself, as well as on the developing brain. One mechanism and effect pattern that is well described in rats is TPO inhibition (reducing TH synthesis) leading to activation of the hypothalamic-pituitary-thyroid axis (HPT-axis). In this scenario, there is a dose-dependent correlation between reduced serum T4 concentrations and altered brain development manifesting with both morphological and behavioral effects [512]. However, for some TH system disrupting chemicals not acting through this TPO-mediated mechanism, it is unclear if there is the same correlation between low serum T4 concentrations and TH-mediated brain effects. This includes environmental chemicals that presumably disrupt the TH system by either binding to TTR or induce metabolizing enzymes in the liver, for instance triclosan [13, 14], polychlorinated biphenyls (PCBs) [15], the perfluorinated compound perfluorohexane sulfonate (PFHxS) [14, 16] and potentially also the polybrominated diphenyl ether (PBDE) mixture DE-71 (PBDE) [1719].

Now banned, PBDEs were for decades used as flame retardants in both industrial and consumer products. Today, human exposure continues due to environmental contamination, persistence and bioaccumulation. Thus, the primary exposure routes are food and house dust [20]. DE-71 is a technical mixture of PBDEs and its congeners are still found in human serum, breast milk and house dust [20, 21]. In humans and animals, exposure to PBDEs has been associated with a range of effects including neurotoxicity, disruption of the reproductive and thyroid hormone systems.

In adult rats DE-71 markedly reduces serum thyroxine (T4) concentrations (>70% reduction), while TSH levels remain unaffected, or slightly increased [17, 2224]. A similar effect pattern is seen in perinatally exposed rat offspring, where DE-71 reduces serum T4 by more than 70% without inducing TSH levels to any great degree [17, 18, 24]. One question is if such marked reductions in T4, without a concomitant compensatory increase in TSH, can perturb neurodevelopment and cause cognitive or other toxicological effects in exposed offspring similarly to those caused by TPO-inhibitors. Based on a small number of developmental exposure studies with DE-71, it may be assumed that it does not. However, no definite conclusions can be drawn from the available data.

Previous toxicity studies with perinatal DE-71 exposure have reported marked reduction in T4 (70–90% in high exposure groups), yet without consistent adverse behavioral effects in the offspring [1719]. In some of the studies, however, group sizes were relatively small which could impair their ability to detect subtle effects. In addition, the studies performed cognitive testing at different developmental ages using slightly different methodologies. Exposure windows also varied slightly between studies, as did the rat strains used; Long-Evans [17], Sprague-Dawley [18] or Wistar [19]. Finally, the potential effects on HPT-axis regulation remains poorly examined. Three studies report on TSH levels in DE-71 exposed pups; one with a 30% increase [18] and two others with no changes to TSH [17, 24], and there are no thorough histological examinations of pup thyroid glands. Together, this makes it difficult to conclude on overall effect patterns on the TH system after perinatal exposure to DE-71.

To enable a more informed conclusion about any potential adverse effects on behavior following developmental exposure to DE-71, as well as address other unclear relationships as outlined above, we performed a robust in vivo toxicity study. The study design and endpoints are aligned with our previous studies of TPO inhibitors propylthiouracil, methimazole and amitrole [6, 10] (refer to Table 1 for summary results).This was done to answer the outstanding question whether there is a direct correlation between low serum T4 and neurobehavioral effects of DE-71, since only few and sporadic effects have been found in other studies investigating neurodevelopmental effects [1719]. Furthermore, we wished to clarify if DE-71 can activate the HPT-axis in a manner consistent with TPO inhibition and whether it is plausible that DE-71 causes dose-dependent and correlated effects on serum T4 and TH-mediated brain development.

Table 1. Developmental DE-71 exposure studies of the thyroid hormone system and brain development in rats.

Exposure to DE-71 TH/TSH Thyroid gland Developmental neurotoxicity and hearing Reference
Studies including only thyroid hormone system endpoints      
0, 0.1, 1, 10 or 30 mg/kg/day to SD dams GD6-PND21 (wafer, oral) (n = 6–9) Dam PD21 tT4 and fT4↓ up to ~50%, tT3↔, TSH↔
Pup PD21 tT4↓ up to 85%, fT4↓ up to 75%, tT3↔, TSH↔
- - [34] (Bansal et al., 2014)
0 or 18 mg/kg/day to SD dams GD6-LD18 (intragastric) (n = 3–7) Dam LD19 tT4↓45%, tT3↔, TSH↔
Pup PND18 tT4↓75%, tT3↔, TSH↔
Dam thyroid gland weights were obtained but results not stated - [24] (Ellis-Hutchings et al., 2006)
0, 1.7, 10.2 or 30.6 mg/kg/day to LE dams from GD6-PND21 (oral gavage) (n = 7–9) Male pup: PND4 tT4↓ up to 50%, tT3↔
PND21 tT4↓ up to 75%, tT3↔
- - [4] (Szabo et al., 2009)
0, 1, 10 or 30 mg/kg/day to LE dams GD6-PND21 (oral gavage) (n = unclear, maybe 38–48 dams per group for both GD20 and PND22) Dam GD20: tT4↓ 48% in high dose, tT3↔
Dam PND22: tT4↓45%, tT3↔
Fetal GD20: tT4↓ (more than 15%, control group very close to LOQ)
Pup PND4: tT4↓ up to 40%, tT3↔
Pup PND14: tT4↓ up to 66%, tT3↔
- - [35] (Zhou et al., 2002)
Studies also including developmental neurotoxicity endpoints      
0, 0.3, 3.0 or 30 mg/kg/day to SD dams GD1-PND 21 (cookie, oral) (n = 20–22 litters, TH: n = 9–10, TSH: n = 20–22, thyroid histo n = 8–10) Dam PND21: tT4 and tT3 ↓ (data not shown)
Male pup PND21: tT4↓ up to ~95%, tT3↓ up to 40%
Female pup PND21: tT4↓ up to ~90%, tT3↓ up to 40%
Pup PND21, TSH↑ ~30% in high dose
Male pup PND21: increased epithelial cell height in high dose Brain weight PND21, 50, 105, 250: ↔ except PND21 raw brain weight ↓ in low dose and relative brain weight ↑ in high dose PND21 (both sexes),
Motor activity PND 16, 55, 110 and 230: ↔, except small changes in rearing PND110
Acoustic startle PND20 and 90: potentiation on PND90 indicating delayed effects on sensory reactivity
Beam test PND 33, 60: ↔
Emergency latency PND35, 80: ↔
Morris Water Maze PND 235: ↔
Nicotine-induced activity PND450: ↔
[18] (Bowers et al., 2015)
0 or 30 mg/kg/day to Wistar rat pups PND5-22 (oral gavage) (Open field: n = 17, radial maze: n = 11, T4: n = 10) Male pup PND 23: tT4↓ ~50%
Female pup PND 23: tT4↓ ~50%
Male pup PND23: thyroid gland weight↔
Female pup PND23: thyroid gland weight↔
Brain weight PND23↔
Open field PND42 and 70: ↔ motor activity both sexes
RAM PND100: reference memory deficit, females only
[19] (De-Miranda et al., 2016)
0, 1.7, 20.2 or 30.6 mg/kg/day to LE dams GD6-PND21 (oral gavage) (n > 15 per group, n = 8–13 in FOB, n = 7–8 open field, TSH n = 5–12) Dams PND22: tT4↓ up to ~40%, tT3↔, TSH↑ ~130% in high dose
Male pups PD4: tT4↓ 52% in high dose, TSH↔
Male pups PD7: tT4↓ 60% in high dose, TSH↔
Male pups PD14: tT4↓ up to 78%, TSH↔
Male pups PD21: tT4↓ up to 74%, TSH↔
Female pups PD4: tT4↓ 56% in high dose, TSH↔
Female pups PD7: tT4↓ 50% in high dose, TSH↔
Female pups PD14: tT4↓ up to 80%, TSH↔
Female pups PD21: tT4↓ up to 76%, TSH↔
- FOB including open field PND24, 60 and 273: ↔, except significant interaction dose*age interaction from PD24-60, but no overall treatment effect on PND60
Motor activity in figure eight, PND 24 and 60: ↔
motor activity (motron) PND~110: ↔
[17] (Kodavanti et al., 2010)
0, 40, 60 mg/kg/day to Wistar dams GD7-PD16 (oral gavage) (n = 19–21) Dam GD15 tT4↓ up to 60%, tT3↓ up to 25%, TSH↔
Pup PD8-PD27 tT4↓ ~60% all doses, PD16 tT3↓ ~25% all doses, PD27 tT3↓~15% all doses
Dam PD27 thyroid gland weight↔
Female pup PD16 thyroid weight↔
Male pup PD27 thyroid weight↔
Male PD16 histology: no changes in follicular epithelium, follicular morphology, stroma or c-cells but increased minimal vacuolation of follicular colloid in high dose
Motor activity PD21 and PD79: ↔
Morris water maze at 4.5–6 months of age: ↔
Hearing function at 7.5–8 months: ↔
This study
For comparison: studies with exposure to TPO-inhibitors in same or similar studies      
0, 0.8, 1.6 or 2.4 mg/kg/day PTU to Wistar dams GD7-PD17 (oral gavage) (n = 18–21) Dam GD15: tT4↓ with up to ~60%
Pup PND16: tT4↓ with up to ~85%
Pups PND16: thyroid gland weight↑
Pup histology PND16: marked changes with hyperplasia and hypertrophy of epithelial cells, papillary projections into lumen and reduced lumen size
Motor activity: PND 14↓, PND17↔, PND23↑, 16 weeks: ↑
Morris water maze, weeks 8–9: ↔
RAM, males 5–6 months: ↓ learning and memory
Hearing, adult offspring: ↓
[10] (Axelstad et al., 2008)
0 or 30 mg/kg/day PTU to Wistar rat pups PND5-22 (oral gavage) (Open field: n = 17, radial maze: n = 11, T4: n = 10) Male pup PND 23: tT4↓ >95%
Female pup PND 23: tT4↓ >95%
PND23: thyroid gland weight↑, both sexes Brain weight, relative PND23: ↑, both sexes
Open field PND42 and 70: ↑motor activity, both sexes
RAM PND100: working and reference memory learning deficits, both sexes
[19] (De-Miranda et al., 2016)
0, 8 mg/kg/day MMI, 16 mg/kg/day MMI, 25 or 50 mg/kg/day amitrole SD dams GD7-PD22 (oral gavage) (n = 12). Effects are similar in both MMI and amitrole unless otherwise stated. Dam GD15: tT4↓ up to ~60%, tT3↓23% in high dose amitrole, TSH↑ up to ~800%
Dam PD22: tT4↓ up to ~60% in MMI and 90% in amitrole, tT3↑30% in low dose MMI, TSH↑ up to ~800%
Male pup PD16: tT4↓ up to ~80–90% in high dose, tT3↓25–35% in high dose, TSH↑330–425% in high dose
Female pup PD17: tT4↓ up to ~80–90% in high dose, tT3↓25–30% in high dose, TSH↑250–360% in high dose
Dam PD22: thyroid gland weight ↑
Male pup PD16: thyroid gland weight↑
Female pup PD17: thyroid gland weight↑
Male pup PD16 histology (n = 4): hyperplasia/hypertrophy, irregular follicles, reduced lumen size and colloid depletion
Motor activity, offspring PND21:↑ [6] (Ramhøj et al., 2022)

Abbreviations: f: free, LD: lactation day, LE: Long-Evans, MMI: Methimazole, PND: postnatal day, PD: pup day, PTU: propylthiouracil, RAM: radial arm maze, SD: Sprague-Dawley, T4: thyroxine, T3: 3,3´,5-tri-iodothyronine, TH: thyroid hormones, t: total, TSH: thyroid stimulating hormone

All doses given in mg/kg bodyweight/day.

Materials and methods

Chemicals

The test compound was DE-71 (a technical mixture of penta-brominated diphenyl ethers (BDE), lot 7550OK20A), a commercial mixture of PBDEs (kind gift from Dr. Kevin Crofton at the U.S. Environmental Protection Agency). A gas chromatography coupled with high-resolution mass spectrometry (GC-HRMS) analysis of the congener content in our DE-71 solutions showed an approximate distribution of congeners in this lot of DE-71 as follows: ~29% tetraPBDE (BDE-47), 59% pentaPBDE (of which ~50% BDE-99 and ~9% is BDE-100) and ~9% hexaPBDE (of which ~5% BDE-153 and ~4% is BDE-154). Corn oil (Sigma-Aldrich, St. Louis, MO, USA) was used as control compound and vehicle for all treatments.

Animals and treatment

Two animal studies were conducted as depicted in Fig 1, using 40 and 66 time-mated pregnant Wistar rats (HanTac: WH, Taconic Europe, Ejby, Denmark) that were received on gestation day (GD) 3 of pregnancy (day of plug-detection designated GD1) and pseudo-randomly divided into groups. The expected day of delivery, GD23, was designated PD1 irrespective of actual day of delivery. A detailed description of experimental setup, reproductive toxicity outcomes, postnatal growth and disruption of the reproductive hormone systems have been reported previously [25]. In short, we found no evidence for overt toxicity in dams or pups, but shorter anogenital distance and reduced prostate weight in male offspring, as well as decreased mammary gland outgrowth in both sexes [25].

Fig 1. Study design for two developmental toxicity studies with the DE-71 technical mixture of brominated flame retardants.

Fig 1

Study 1 assessed early postnatal thyroid hormone disruption and toxicity while Study 2 was used for examination of later postnatal thyroid hormone system disruption, liver and later in life effects on behavior, learning and hearing function. Bw: body weight, GD: gestation day, PBDE: polybrominated diphenyl ethers (DE-71), PD: postnatal day. T3: 3,3´,5-tri-iodothyronine, T4: thyroxine. TSH: thyroid stimulating hormone. The toxicity data and reproductive effects are reported elsewhere [25]. Timeline not drawn to scale.

Study 1 comprised 4 treatment groups of 10 dams each, exposed to vehicle control (corn oil), or DE-71 at 20, 40 or 60 mg/kg bodyweight (bw)/day from GD7 to PD14, except the day of delivery. Study 2 was conducted in two balanced blocks and comprised three treatment groups of 22 dams each, exposed to vehicle control (corn oil), or DE-71 at 40 or 60 mg/kg bw/day from GD7 to PD16, except day of delivery. All exposure were administered by oral gavage at a constant volume of 2 ml/kg bw/day. Dams were housed pairwise in semitransparent plastic cages (15 × 27 × 43 cm) until GD17 and individually thereafter. Conditions were environmentally controlled and with reverse light/dark cycles (light from 9 pm-9 am). The animals were provided standard Altromin 1314 diet ad libitum (soy and alfalfa-free, Altromin GmbH, Lage, Germany). The iodine and selenium contents were 1.52 mg/kg and 0.26 mg/kg, respectively. Acidified tap water was provided ad libitum in PSU bottles (84-ACBTO702SU, Tecniplast, Buguggiate, Italy).

In Study 2, one male and one female pup per litter were weaned (PD27) and housed pairwise with an animal of the same treatment group (or with a sibling if none were available). These offspring were then used for motor activity assessments on PD79, testing in the Morris water maze for 8 days at 4.5–6 months of age and testing of hearing function on one day at approx. 7–8 months of age, as described below.

Animal experiments were conducted at the DTU National Food Institute’s facilities (Mørkhøj, Denmark). Ethical approval was obtained from the Danish Animal Experiments Inspectorate, with authorization number 2012-15-2934-00089 C4. The experiments were overseen by the National Food Institute’s in-house Animal Welfare Committee for animal care and use.

Organ weights, tissue and serum sample collection

In both studies all animals, as specified below, were killed by decapitation under CO2/O2 anesthesia and trunk blood collected.

Study 1 was terminated on PD14 and livers from the dams excised and weighed. Tongue blood samples were taken from live dams on GD15. Depending on the number of pups in the litters, blood samples were pooled from 2–4 pups on PD3 and PD8. On PD14, plasma was pooled separately for male and female pups.

In Study 2, remaining pups (except those weaned) and dams were terminated on PD27. From dams liver and thyroid glands were excised and weighed. Necropsies were performed on one male and one female pup per litter on PD16 and PD27. Livers were weighed and on PD16 a piece was fixed in 10% formalin and subsequently processed and embedded in paraffin for histology. Thyroid glands were excised and weighed from PD16 female pups and PD27 male pups. For PD16 males, the thyroid glands were excised attached to a piece of the thyroid cartilage and fixed in 10% formalin, then tissue processed and embedded in paraffin. Tongue blood samples were taken from dams on GD15. Blood was collected from one male and one female pup per litter on PD16. On PD27 blood samples were pooled separately for males and females and included all remaining pups not weaned for later in life tests.

All blood samples were collected in heparinized Eppendorf/vacutainer tubes and stored on ice until centrifugation for 10 min at 4°C and 4000 rpm. The plasma was collected and stored at -80°C until analysis.

Hormone analysis

Serum total T4 and 3,3´,5-tri-iodothyronine (T3) concentrations were measured at different times in the two studies, as detailed in Fig 1. Total T4 and T3 concentrations were analyzed by electrochemiluminescence-immunoassay (ECLIA)–photoncount using a Cobas 8000 E-modul at the Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark.

In Study 2 serum TSH were assessed in dam tongue blood on GD15 and in blood from PD16 pups. TSH concentrations were assayed according to manufacturer’s instructions using a TSH rat ELISA kit (DEV9977) together with a Rat Control (DEV99RC) both from Demeditec Diagnostics GmbH (Kiel, Germany).

Histological evaluation of thyroid glands and liver

Two sections each from PD16 thyroid glands and livers were stained with hematoxylin and eosin (H&E) following standard protocols. Thyroid glands of male offspring were assessed for follicle size and shape (presence of papillary projections), vacuolation of follicular colloid, type of follicular epithelium (flattened to columnar and position of nucleus), hyperplasia of follicular epithelium, c-cell hyperplasia, vascularization and fibrosis.

Livers from male and female offspring were assessed for hypertrophy (severity and localization) and vacuolation (severity) of hepatocytes. Vacuolation was defined as large vacuoles displacing the nucleus of hepatocytes.

All histological evaluations were performed by a veterinary pathologist and scoring was done blinded to exposure group.

Motor activity and habituation

Motor activity and habituation was assessed in prepubertal male and female pup offspring on PD21, and in the weaned adult offspring on PD79. Testing protocols were as previously described [6]. Briefly, each pup was placed in sound and light insulated activity boxes that records horizontal activity via interruptions of adjacent photo beams. Testing took place for 30 min during which the number of photo beam interruptions was registered (via computer in adjoining room) in 10 periods of 3 min. Total counts during the 30 min represents total motor activity levels. Habituation was assessed by the average counts during the initial (0–9 min), middle (10–21 min) and last part of the test (22–30 min). In addition, activity counts were averaged during the first (0–15 min) and second half of the test (16–30 min).

Learning in the Morris water maze

Learning was assessed in the weaned adult offspring distributed into three new blocks and with testing performed in the Morris water maze with animals ages PD132-PD176 for a period of 5+3 days (separated by two days without testing), in a pool with a diameter of 220 cm. The animals were challenged to learn to find the location of a platform hidden just below the water surface in the pool surrounded by optical cues. The platform was transparent, circular and placed on a solid stand 1 cm below the water surface. Every animal was in four trials per day placed in the pool at four different starting points and allowed to search for the platform. The trial was completed when the animal climbed onto the platform. If the platform had not been located within 60s, the animal was led to the platform by hand and allowed to sit on the platform for 20 seconds before being dried and returned to the cage. Endpoints included latency to locate the platform, path lengths and swimming speeds which where all registered by a camera equipped with a tracking system (Viewpoint video-tracking system, Sandown Scientific, Middlesex, England).

Auditory function

After the maze testing, a subset of 12 males and females (maximum one of each sex from every litter) per group were subjected to test of hearing function over the course of 4 days between PD216-233. Animals were anesthetized with 1.8 ml/kg bw of a mixture of zolazepam 12.9 mg, tiletamine 12.9 mg, xylazine 1.8 mg, fentanyl 10.3 μg in 0.9% NaCl per 1 ml. Animals roused after approximately 2 hrs and were killed on the same or the following day. Testing procedures and equipment were as previously described [10, 26]. Briefly, hearing was assessed by measuring the distortion product otoacoustic emissions (DPOAE). DPOAE was measured as the amplitude of the cubic distortion product (CDP) from two tones generated by a two-channel tone generator with phase control (HP 8904) and the probe microphone output feeding into a FFT spectrum analyzer (HP 35670A). The first tone (f1) was always 10 db higher than the second tone (f2) and there was a fixed ratio between them of f2/f1 = 16713 = 1.23. Distortion product diagrams (DP-grams) were generated by measuring CDP at fixed levels of primary tones across frequencies (2 to 70 kHz), based on 64 time-averaged recordings. DPOAE input/output curves were made at f2 = 4096Hz and 32384 Hz by measuring CDP amplitude at varying levels of primary tones.

Statistical analysis

Data from continuous endpoints with normal distribution and homogeneity of variance were tested by ANOVA, with appropriate covariates included in the statistical analysis (e.g. body weight for organ weights and motor activity). Dunnett’s post-hoc test was applied to account for multiple testing with the statistical significance level set at 0.05. Litter effects were accounted for by only analyzing one pup per litter or by including the litter as an independent random and nested factor in the analysis. Hearing data was analyzed by ANOVA with exposure level and sex as factors, assuming unequal variance between groups.

A 2-sided Fisher’s exact test was used for histology data. First a rxk Fisher’s exact test was used (including more than 2 groups and more than 2 scores) to detect differences in the distribution of scores in all the groups. To determine if one group differed from controls, a 2xk Fisher’s exact test was performed. For dichotomous data, a 2x2 Fisher’s test was used to compare two groups.

SAS Enterprise guide 4.3 (2010) (SAS Institute Inc, Cary, NC, USA) and GraphPad Prism 5 (Graphpad Software, San Diego, CA; USA) was used for statistical analysis. Statistical analysis of hearing data was performed in SYSTAT Software Package v. 9.

Results

Dam thyroid hormone system disruption

We assayed dam TH system disruption in the pregnant animals. This was done because the fetus is entirely dependent on maternal transfer of T4 to the fetal circulation during early development. On GD15, dam T4 and T3 levels were dose-dependently reduced by DE-71 exposure (<50% and <85% of controls, respectively, for T4 and T3) (Fig 2A and 2B). There were no statistically significant effects on TSH concentrations, albeit values appeared more variable in exposed group compared to controls (Fig 2C).

Fig 2. Dam serum T4, T3 and TSH concentrations on GD15 after 7 days of exposure to DE-71.

Fig 2

(A) Dam serum T4 concentrations as % of control in Study 1 and Study 2. Study 1: n = 8–9 except PBDE-20 with n = 6. Study 2: n = 19–21. Mean + SEM. (B) Dam serum T3 as % of control (Study 2). Mean + SEM. n = 19–21. (C) Dam serum TSH concentrations (Study 2). Mean + SEM. Individual data points with mean and whiskers indicating SEM. n = 9–11. **p<0.01. GD: gestation day, PBDE: polybrominated diphenyl ethers (DE-71). T3: tri-iodothyronine, T4: thyroxine. TSH: thyroid stimulating hormone.

Pup thyroid hormone system disruption

Postnatally, brain development depends on the offspring’s own TH production. All doses of DE-71 markedly reduced postnatal T4 concentrations to 25–45% of control levels (Fig 3A). On PD16 and PD27, T3 levels were reduced to ~75–85% of controls by DE-71 exposure (Fig 3B). DE-71 exposure was discontinued on PD16, but there was only slow recovery in T4 and T3 levels between PD16 and PD27 (Fig 3A and 3B).

Fig 3. Pup serum T4 and T3 concentrations during postnatal development.

Fig 3

(A) Pup serum T4 (% of control) in Study 1 and 2 covering PD8 to PD27 T4 was statistically significantly decreased at all doses at all points in time. Study 1: n = 6–8, Study 2: n = 19–21 litters. Mean + SEM. (B) Pup serum T3 concentrations PD16 and PD27 (Study 2). n = 19–21. Mean + SEM. **p<0.01. PBDE: polybrominated diphenyl ethers (DE-71), PD: postnatal day, T3: tri-iodothyronine, T4: thyroxine.

Effects on the liver

TH system disruption can arise from different mechanisms, one of which is liver enzyme induction (microsomal enzyme inducers). We, therefore, looked for effects in dam and pup livers. Dam liver weights were increased dose-dependently in all exposure groups on PD14 in Study 1 (~20% in high dose) (Fig 4A). The increase was observed for both absolute liver weight analyzed with body weight as covariate and for relative weights (data in S1 File). There was no effect on body weights. By PD27, in Study 2, liver weights were similar between groups.

Fig 4. Effects of DE-71 exposure from GD7-PD14/16 on dam and pup liver weights and histology.

Fig 4

(A) Dam liver weights were increased dose-dependently in Study 1 on PD14, while there were no effects on PD27 in Study 2. n = 7 in Study 1, n = 19–21 in Study 2. Mean + SEM. (B) Male and female pup liver weights PD16 and PD27. n = 17–21. Mean + SEM. (C) Severity of hepatocytic hypertrophy in male and female offspring PD16. Centrilobular hypertrophy was observed in all exposed animals. Number of assessed offspring shown in each bar. n = 36–40. (D) Male PD16 liver from control (top), high-dose presenting with severe centrilobular hepatocytic hypertrophy (middle) and high dose with moderate hepatocytic vacuolation (bottom). Arrows show examples of large macrovesicular vacuoles in hepatocytes (E) Severity of hepatocytic vacuolation in male and female offspring PD16. Significantly increased incidence of vacuolation was seen in exposed offspring. Number of assessed offspring shown in each bar. n = 36–40. *p<0.05, **p<0.01. Scalebar = 100 μm. PBDE: polybrominated diphenyl ethers (DE-71), PD: postnatal day.

Pup liver weights were markedly increased (up to ~50%), particularly on PD16, at the end of exposure (Fig 4B). By PD27 the increase was less pronounced, demonstrating some recovery after exposure ceased. Histological evaluation of pup livers revealed increased hypertrophy and vacuolation of hepatocytes with increasing dose of DE-71 (Fig 4C–4E). Hypertrophy was seen in all exposed animals, and severity increased with increasing dose (Fig 4C). One control male displayed marginal signs of hypertrophy. Hypertrophy of hepatocytes was localised to the centrilobular areas. No microvesicular vacuolation was observed. Vacuolation of hepatocytes was only seen in exposed pups and the severity of vacuolation increased with dose (Fig 4E).

The hypothalamic-pituitary-thyroid axis

TH system disruption by microsomal enzyme inducers appears to cause two different effect patterns within the HPT-axis. Some enzyme inducers, such as phenobarbital, reduce serum T4 concentrations with a concurrent activation of the HPT-axis, resulting in increased TSH levels to stimulate TH production in the thyroid gland [27, 28]. This leads to increased thyroid gland weight and histological changes. In this study, DE-71 exposure reduced T4 without affecting TSH levels or thyroid gland weights, either in PD16 and PD27 pups (Fig 5A and 5B) or PD27 dams (Figs 2C & 5B). No changes in the follicular epithelium, follicular morphology, stroma or c-cells were evident in thyroid glands of PD16 male pups. However, we observed a dose-dependent increase in vacuolation of follicular colloid with a statistically significant higher incidence in the high dose-group compared to controls (Fig 5C). The vacuolation was negligible and no vacuolation of the follicular epithelium was observed in relation to vacuolation of colloid. This could be signs of increased activation of the thyroid follicles. However, the lack of effects on epithelium and follicular morphology indicates that the activation was minor, if any. Taken together, our results indicate that the DE-71 mixture is a microsomal enzyme inducer which does not cause an activation of the HPT-axis in rat offspring.

Fig 5. Effects on the hypothalamic-pituitary-thyroid axis in rat offspring exposed to DE-71 during development.

Fig 5

(A) TSH concentrations in PD16 male and female offspring. Individual data points shown with mean and SEM whiskers. n = 7–8. (B) Thyroid gland weights in female offspring PD16, male PD27 and dams PD27. Females: n = 19–21, males: n = 15–17, Dams: n = 19–21. (C) Vacuolation of thyroid gland follicular colloid in male PD16 offspring. Left: incidences of vacuolation and severity, number of assessed male pups shown inside bars. Upper right: Thyroid gland with no vacuolation of follicular colloid. Lower right: thyroid gland with minimal vacuolation (arrows) of follicular colloid. *p< 0.05. Scalebar = 50 μm. PBDE: polybrominated diphenyl ethers (DE-71), PD: postnatal day, TSH: thyroid-stimulating-hormone.

Offspring neurobehavior

Motor activity levels and habituation were tested in prepubertal (PD21) and adult (PD79) offspring. We found habituation (decreasing activity levels over the course of the test) at both ages in males and females and observed the expected sex difference in adulthood, i.e. higher activity levels in females than in males. There were no significant treatment-related effects of developmental DE-71 exposure on general activity (Fig 6), nor on habituation in males (Fig 6) or females (data in S1 File) at any age. Learning was tested in the Morris water maze at approximately 5 months of age. We found improved performance over the course of the test, demonstrating a functional assay. However, we found no effects of developmental exposure on distance, latency to reach platform or swimming speed (Fig 6C). This indicates that DE-71 exposure did not affect learning as assessed by this simple behavioral assay.

Fig 6. Neurobehavior in rat pups exposed to PBDEs during development.

Fig 6

(A) Total motor activity (total counts in 30 min) levels in PD21 male and female offspring and habituation (average activity counts per 3 min period) in male offspring. Control and PBDE-40: n = 18–19, PBDE-60: n = 14–15. (B) Total motor activity levels in PD79 adult male and female offspring and habituation in male offspring. Control and PBDE-40: n = 17–20, PBDE-60: n = 15. (C) Mean distance travelled and time spent to reach hidden platform in the Morris water maze (8 days of testing at 4.5–6 months of age). n = 18–20. Mean + SEM. PBDE: polybrominated diphenyl ethers (DE-71), PD: postnatal day.

Offspring hearing function

We have previously shown how developmental hypothyroidism results in increased hearing thresholds and decreased Cubic Distortion Product (CDP) with loss of activity in the outer hair cells spread equally over the basilar membrane in the cochlea [10]. We performed the same tests on the DE-71 exposed animals but found no differences compared to control animals (Fig 7).

Fig 7. Hearing function in adult 7.5–8 months old male and female offspring exposed to PBDEs during development.

Fig 7

(A) Distortion product diagram of cubic distortion product at all tested frequencies (2 to 70 kHz). Data represent group means, black curve represents background noise ± 95% confidence interval. (B) Average cubic distortion product for f2 at 4 and 32 kHz. PBDE: polybrominated diphenyl ethers (DE-71). n = 11–12.

Discussion

One of the main aims of this study was to clarify if there is a dose dependent correlation between low serum T4 levels caused by developmental exposure to DE-71 and neurobehavioral changes in the rat offspring. Based on our results, and those of previous studies, the answer appears to be no. This is despite the fact that perinatal exposure to DE-71 markedly reduces plasma T4 and T3 concentrations throughout development. Notably, however, the HPT-axis does not seem to be activated by this marked reduction in T4 as, for instance, is the case with hypothyroidism induced by propylthiouracil (PTU) [10]. In PTU-exposed animals, TSH levels increase in response to a drop in T4. Regardless, a severe reduction in T4 did not result in adverse effects on behavior or hearing. It thus appears that thyroid hormone system disruption by DE-71 does not result in the severe hypothyroidism and associated effects that can be ascribed to PTU and other potent TPO-inhibiting compounds [68, 10].

As discussed in the introduction, several studies have examined the potential effects of DE-71 on the thyroid hormone system and neuroendocrine development. However, it is challenging to draw general conclusions since study designs vary considerably. This is also the conclusion reached by a systematic review of developmental neurotoxicity by PBDEs in animal studies [29]; nevertheless the evidence for neurotoxicity in humans is quite strong [3033]. In Table 1, we have summarized the key rat studies of DE-71 and reported effects in order to integrate our new results in a more holistic analysis. From this synthesis it is evident that DE-71 induces very few effects on behavioral endpoints across developmental toxicity studies.

There is also an obvious decoupling between low serum T4 levels and changes to brain development as assessed in standard neurobehavioral tests. The dose-dependent correlations seen with TPO inhibitors simply do not occur with DE-71 exposure.

One of the primary target organs of PBDEs is the liver. We found a pronounced increase in liver weights and histological changes in DE-71 exposed animals, which is consistent with microsomal enzyme induction reported by others. More specifically, DE-71 can induce enzymes related to TH metabolism and excretion [4, 3537]. This suggests that increased hepatic clearance of THs contributes to the reduction in serum T4. Notably, PBDEs also possess the ability to bind and displace T4 from the serum thyroid hormone transport protein TTR, with hydroxylated metabolites of PBDEs having particularly high affinity [3840]. In vivo these two mechanisms may act together to increase excretion of thyroid hormones and produce the phenotype of low serum T4 concentrations. How this relates to the lack of HPT-axis activation, however, remains unexplained.

DE-71 exposure severely reduced serum T4 concentration throughout postnatal development. Comparing this to other studies with developmental exposure to DE-71 (Table 1) shows that there is concordance between studies and strong evidence to conclude that DE-71 consistently reduces serum T4 in perinatally exposed pups. It also correlates with T4 effects in similar developmental toxicity studies with TPO inhibitors. With regard to T3, however, few studies have found, or even measured, any effect on serum concentrations in pups exposed to DE-71. Three studies with small group sizes report no effect on T3 levels [4, 24, 35], while one report reduced serum T3 in both male and female pups on PD21 [18] (Table 1). We also found reduced serum T3 levels in PD16 pups measured across relatively large group sizes of 19–21. This strengthens the evidence for DE-71 causing a reduction in pup T3 concentrations, yet the available data is inconsistent.

The thyroid gland is the site of TH synthesis and the target of TSH and thus natural to assess for potential thyroid hormone system disruption and HPT-axis activation. That is, thyroid gland weight and histology should be scrutinized even though DE-71 does not appear to increase TSH levels in the majority of studies. With regard to TSH, our study, together with two others, observed no effect on pup serum TSH [17, 24] while a fourth study reported a 30% increase [18]. This latter study also found follicular epithelium cell height to be increased in PD21 pups, but did not investigate other adverse effects in the thyroid glands [18] (Table 1). In fact, the only other assessment of thyroid glands is a study that found no effects on pup thyroid gland weight after DE-71 exposure [19] (Table 1). Thus, assessments of thyroid gland weight and histology are scarce and our study is the first to report on a full histological assessment of DE-71-exposed pup thyroid glands. This assessment revealed no marked effects, which is in contrast to what is reported in PD16 pups developmentally exposed to PTU, MMI or amitrole [6, 10, 41, 42]; however, we did find minimal effects on colloid vesicles. Taken together, exposure to DE-71 does not appear to activate the HPT-axis in perinatally exposed rat pups, and only induces marginal, if any, changes to thyroid gland morphology.

Growing evidence suggests that rodent models for hypothyroxinemia-like effect patterns are not sufficiently sensitive to determine if a TH system disrupting chemical possess developmental neurotoxicity potential [1]. That is, the effects on the brain, if present, are not pronounced enough to be detected by standard neurotoxicity assays, but the TH system disrupting potential is great enough to be of concern to human health. The fact is that our current experimental conditions limit our ability to measure and determine if there is an effect or not due to endpoint sensitivity. Firstly, dose-response studies of effects of TH deficiency induced by TPO inhibitors show that serum and brain THs need to be severely reduced in foetuses and postnatal pups before statistically significant effects on brain development are observed [1, 6, 9, 10, 12, 42, 43]. Thus, current endpoints for neurotoxicity are not sensitive enough to detect developmental TH system disruption. Secondly, there likely is a discrepancy between serum and brain TH concentrations in rodents subject to chemically induced hypothyroxinemia-like conditions. Here, brain hormones can be less affected despite pronounced effects on serum hormones [14], opposite to the relationships seen with PTU exposure [9, 44]. Whether this also applies to DE-71 exposed animals should be investigated in future studies. Regardless, the simple neurobehavioral tests used herein, and in other studies, cannot identify adverse neurological effects of DE-71 induced TH-system disruption in rat offspring.

While our neurobehavioral assays, and potentially also the rodent brain, may be relatively insensitive to TH deficiency, there is no question that the situation is very different for the human brain. In humans, severe lack of TH during development has profound consequences for brain development. All the while there is also a substantial body of literature showing that even slightly reduced serum T4 with no effects on TSH, so-called hypothyroxinemia, is enough to impair child brain development. This is evident from epidemiological studies, that find decreased IQ, altered white-to-grey matter ratio, altered motor and language development, and increased risk of developing neurobehavioral disorders such as autism, ADHD and schizophrenia [4551]. Thus, while it is challenging to test rodent brain function for effects of TH system disruption, the evidence from humans is that hypothyroxinemia does negatively impact human brain development. Accordingly, the widespread exposure of humans to TH system disrupting chemicals is of great concern if we are to protect human cognition and health for future generations.

Concluding remarks

Perinatal exposure to DE-71 reduces serum T4 markedly in postnatal rat pups, but without a concomitant increase in serum TSH, i.e. a hypothyroxinemia-like response. Based on data herein and from historical studies, there is no clear correlation between significantly lower serum T4 levels and adverse effects as assessed by standard neurobehavioral tests in rats. This contrasts with the correlations seen for TH system disruption by TPO inhibitors, where low serum T4 correlates with TH-mediated effects on the brain. To address this conundrum, future studies should aim to measure TH levels also in target tissues, such as the brain, and include endpoints that are specific to TH system disruption. Only then can we answer the outstanding question if the absence of adverse neurobehavioral effects in DE-71 exposed pups are due to decoupling of systemic TH concentrations and local TH concentrations in the brain. Importantly, however, it should be noted that a reduction in serum THs is in itself of great concern to human health. From what we know, the human brain is most likely very sensitive to any alteration in thyroid status of pregnant women and their developing foetuses. In humans TH system disruption of any kind–hypothyroidism, hypothyroxinemia, or otherwise–is cause for concern as regards brain development.

Supporting information

S1 File. Datasets.

(XLSX)

Acknowledgments

We would like to thank Tommy Licht Cederberg (National Food Institute, Technical University of Denmark) for the DE-71 congener analysis.

We thank Mette Voigt Jessen, Heidi Broksø Letting, Lillian Sztuk, Dorte Lykkegaard Korsbech, Birgitte Møller Plesning, Ulla El-Baroudy, Sarah Grundt Simonsen, Lene Ravn, Eva Terrida and Lasse Laub-Ekgreen for excellent technical assistance. We also thank Anne Ørngreen and staff for animal care and husbandry.

Data Availability

All relevant data are within the manuscript and its Supporting Information file.

Funding Statement

This study was funded by the Danish Environmental Protection Agency, Ministry of Environment and Food of Denmark. KS Hougaard received support from FFIKA, Focused Research Effort on Chemicals in the Working Environment, from the Danish Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Gilbert ME, O’Shaughnessy KL, Axelstad M. Regulation of thyroid-disrupting chemicals to protect the developing brain. Endocrinology. 2020;161: 1–17. doi: 10.1210/endocr/bqaa106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Howdeshell KL. A model of the development of the brain as a construct of the thyroid system developing a timeline model of thyroid system and brain. Environ Health Perspect. 2002;110: 337–348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Noyes PD, Friedman KP, Browne P, Haselman JT, Gilbert ME, Hornung MW, et al. Evaluating chemicals for thyroid disruption: opportunities and challenges with in vitro testing and adverse outcome pathway approaches. Environ Health Perspect. 2019;127. doi: 10.1289/EHP5297 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Szabo DT, Richardson VM, Ross DG, Diliberto JJ, Kodavanti PRS, Birnbaum LS. Effects of perinatal PBDE exposure on hepatic phase I, phase II, phase III, and deiodinase 1 gene expression involved in thyroid hormone metabolism in male rat pups. Toxicol Sci. 2009;107: 27–39. doi: 10.1093/toxsci/kfn230 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Crofton KM, Gilbert ME, Friedman KP, Demeneix B, Marty MS, Zoeller RT. Inhibition of thyroperoxidase and subsequent adverse neurodevelopmental outcomes in mammals. In: AOPWiki [Internet]. 2019. [cited 1 Jun 2022]. Available: https://aopwiki.org/aops/42 [Google Scholar]
  • 6.Ramhøj L, Svingen T, Frädrich C, Rijntjes E, Wirth EK, Pedersen K, et al. Perinatal exposure to the thyroperoxidase inhibitors methimazole and amitrole perturbs thyroid hormone system signaling and alters motor activity in rat offspring. Toxicol Lett. 2022;354: 44–55. doi: 10.1016/j.toxlet.2021.10.010 [DOI] [PubMed] [Google Scholar]
  • 7.Ramhøj L, Frädrich C, Svingen T, Scholze M, Wirth EK, Rijntjes E, et al. Testing for heterotopia formation in rats after developmental exposure to selected in vitro inhibitors of thyroperoxidase. Environ Pollut. 2021;283: 117135. doi: 10.1016/j.envpol.2021.117135 [DOI] [PubMed] [Google Scholar]
  • 8.Gilbert ME, Ramos RL, McCloskey DP, Goodman JH. Subcortical band heterotopia in rat offspring following maternal hypothyroxinaemia: structural and functional characteristics. J Neuroendocrinol. 2014;26: 528–41. doi: 10.1111/jne.12169 [DOI] [PubMed] [Google Scholar]
  • 9.O’Shaughnessy K, Wood CR, Ford RL, Kosian PA, Hotchkiss M, Degitz SJ, et al. Identification of molecular bioindicators of thyroid hormone action in the fetal and neonatal rat brain. Toxicol Sci. 2018;166: 163–179. doi: 10.1093/toxsci/kfy190 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Axelstad M, Hansen PR, Boberg J, Bonnichsen M, Nellemann C, Lund SP, et al. Developmental neurotoxicity of propylthiouracil (PTU) in rats: relationship between transient hypothyroxinemia during development and long-lasting behavioural and functional changes. Toxicol Appl Pharmacol. 2008;232: 1–13. doi: 10.1016/j.taap.2008.05.020 [DOI] [PubMed] [Google Scholar]
  • 11.Sharlin DS, Tighe D, Gilbert ME, Zoeller RT. The balance between oligodendrocyte and astrocyte production in major white matter tracts is linearly related to serum total thyroxine. Endocrinology. 2008;149: 2527–2536. doi: 10.1210/en.2007-1431 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Goldey ES, Kehn LS, Rehnberg GL, Crofton KM. Effects of developmental hypothyroidism on auditory and motor function in the rat. Toxicol Appl Pharmacol. 1995;135: 67–76. doi: 10.1006/taap.1995.1209 [DOI] [PubMed] [Google Scholar]
  • 13.Axelstad M, Boberg J, Vinggaard AM, Christiansen S, Hass U. Triclosan exposure reduces thyroxine levels in pregnant and lactating rat dams and in directly exposed offspring. Food Chem Toxicol. 2013;59: 534–540. doi: 10.1016/j.fct.2013.06.050 [DOI] [PubMed] [Google Scholar]
  • 14.Gilbert ME, O’Shaughnessy KL, Thomas SE, Riutta C, Wood CR, Smith A, et al. Thyroid disruptors: extrathyroidal sites of chemical action and neurodevelopmental outcome—an examination using triclosan and perfluorohexane sulfonate. Toxicol Sci. 2021;183: 195–213. doi: 10.1093/toxsci/kfab080 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Sharlin DS, Bansal R, Zoeller RT. Polychlorinated biphenyls exert selective effects on cellular composition of white matter in a manner inconsistent with thyroid hormone insufficiency. Endocrinology. 2006;147: 846–858. doi: 10.1210/en.2005-0778 [DOI] [PubMed] [Google Scholar]
  • 16.Ramhøj L, Hass U, Gilbert ME, Wood C, Svingen T, Usai D, et al. Evaluating thyroid hormone disruption: investigations of long-term neurodevelopmental effects in rats after perinatal exposure to perfluorohexane sulfonate (PFHxS). Sci Rep. 2020;10:2672. doi: 10.1038/s41598-020-59354-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Kodavanti PRS, Coburn CG, Moser VC, MacPhail RC, Fenton SE, Stoker TE, et al. Developmental exposure to a commercial PBDE mixture, DE-71: neurobehavioral, hormonal, and reproductive effects. Toxicol Sci. 2010;116: 297–312. doi: 10.1093/toxsci/kfq105 [DOI] [PubMed] [Google Scholar]
  • 18.Bowers WJ, Wall PM, Nakai JS, Yagminas A, Wade M, Li N. Behavioral and thyroid effects of in utero and lactational exposure of Sprague-Dawley rats to the polybrominated diphenyl ether mixture DE71. Neurotoxicol Teratol. 2015;52: 127–142. doi: 10.1016/j.ntt.2015.08.002 [DOI] [PubMed] [Google Scholar]
  • 19.de-Miranda AS, Kuriyama SN, da-Silva CS, do-Nascimento MSC, Parente TEM, Paumgartten FJR. Thyroid hormone disruption and cognitive impairment in rats exposed to PBDE during postnatal development. Reprod Toxicol. 2016;63: 114–124. doi: 10.1016/j.reprotox.2016.05.017 [DOI] [PubMed] [Google Scholar]
  • 20.Klinčić D, Dvoršćak M, Jagić K, Mendaš G, Herceg Romanić S. Levels and distribution of polybrominated diphenyl ethers in humans and environmental compartments: a comprehensive review of the last five years of research. Environ Sci Pollut Res. 2020;27: 5744–5758. doi: 10.1007/s11356-020-07598-7 [DOI] [PubMed] [Google Scholar]
  • 21.Bramwell L, Glinianaia S V., Rankin J, Rose M, Fernandes A, Harrad S, et al. Associations between human exposure to polybrominated diphenyl ether flame retardants via diet and indoor dust, and internal dose: a systematic review. Environ Int. 2016;92–93: 680–694. doi: 10.1016/j.envint.2016.02.017 [DOI] [PubMed] [Google Scholar]
  • 22.Stoker TE, Laws SC, Crofton KM, Hedge JM, Ferrell JM, Cooper RL. Assessment of DE-71, a commercial polybrominated diphenyl ether (PBDE) mixture, in the EDSP male and female pubertal protocols. Toxicol Sci. 2004;78: 144–55. doi: 10.1093/toxsci/kfh029 [DOI] [PubMed] [Google Scholar]
  • 23.Becker RA, Bergfelt DR, Borghoff S, Davis JP, Hamby BT, O’Connor JC, et al. Interlaboratory study comparison of the 15-day intact adult male rat screening assay: evaluation of an antithyroid chemical and a negative control chemical. Birth Defects Res Part B—Dev Reprod Toxicol. 2012;95: 63–78. doi: 10.1002/bdrb.20343 [DOI] [PubMed] [Google Scholar]
  • 24.Ellis-Hutchings RG, Cherr GN, Hanna L a, Keen CL. Polybrominated diphenyl ether (PBDE)-induced alterations in vitamin A and thyroid hormone concentrations in the rat during lactation and early postnatal development. Toxicol Appl Pharmacol. 2006;215: 135–45. doi: 10.1016/j.taap.2006.02.008 [DOI] [PubMed] [Google Scholar]
  • 25.Ramhøj L, Mandrup K, Hass U, Svingen T, Axelstad M. Developmental exposure to the DE-71 mixture of polybrominated diphenyl ether (PBDE) flame retardants induce a complex pattern of endocrine disrupting effects in rats. PeerJ. 2022; 1–18. doi: 10.7717/peerj.12738 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Hougaard KS, Barrenäs ML, Kristiansen GB, Lund SP. No evidence for enhanced noise induced hearing loss after prenatal stress or dexamethasone. Neurotoxicol Teratol. 2007;29: 613–621. doi: 10.1016/j.ntt.2007.07.006 [DOI] [PubMed] [Google Scholar]
  • 27.Hood A, Hashmi R, Klaassen C. Effects of microsomal enzyme inducers on thyroid-follicular cell proliferation, hyperplasia and hypertrophy. Toxicol Appl Pharmacol. 1999;160: 163–170. doi: 10.1006/taap.1999.8752 [DOI] [PubMed] [Google Scholar]
  • 28.Klaassen CD, Hood AM. Effects of microsomal enzyme inducers on thyroid follicular cell proliferation and thyroid hormone metabolism. Toxicol Pathol. 2001;29: 34–40. doi: 10.1080/019262301301418838 [DOI] [PubMed] [Google Scholar]
  • 29.Dorman DC, Chiu W, Hales BF, Hauser R, Johnson KJ, Mantus E, et al. Polybrominated diphenyl ether (PBDE) neurotoxicity: a systematic review and meta-analysis of animal evidence. J Toxicol Environ Heal—Part B Crit Rev. 2018;21: 269–289. doi: 10.1080/10937404.2018.1514829 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Bellanger M, Demeneix B, Grandjean P, Zoeller RT, Trasande L. Neurobehavioral deficits, diseases, and associated costs of exposure to endocrine-disrupting chemicals in the European Union. J Clin Endocrinol Metab. 2015;100: 1256–1266. doi: 10.1210/jc.2014-4323 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Grandjean P, Landrigan PJ. Neurobehavioural effects of developmental toxicity. Lancet Neurol. 2014;13: 330–8. doi: 10.1016/S1474-4422(13)70278-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Attina TM, Hauser R, Sathyanarayana S, Hunt PA, Bourguignon JP, Myers JP, et al. Exposure to endocrine-disrupting chemicals in the USA: a population-based disease burden and cost analysis. Lancet Diabetes Endocrinol. 2016;4: 996–1003. doi: 10.1016/S2213-8587(16)30275-3 [DOI] [PubMed] [Google Scholar]
  • 33.Lam J, Lanphear BP, Bellinger D, Axelrad DA, McPartland J, Sutton P, et al. Developmental pbde exposure and IQ/ADHD in childhood: A systematic review and meta-analysis. Environ Health Perspect. 2017;125. doi: 10.1289/EHP1632 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Bansal R, Tighe D, Denai A, Rawn DFK, Gaertner DW, Arnold DL, et al. Polybrominated diphenyl ether (DE-71) interferes with thyroid hormone action independent of effects on circulating levels of thyroid hormone. Endocrinology. 2014;155: 4104–4112. doi: 10.1210/en.2014-1154 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Zhou T, Taylor MM, DeVito MJ, Crofton KM. Developmental exposure to brominated diphenyl ethers results in thyroid hormone disruption. Toxicol Sci. 2002;66: 105–16. Available: http://www.ncbi.nlm.nih.gov/pubmed/11861977 doi: 10.1093/toxsci/66.1.105 [DOI] [PubMed] [Google Scholar]
  • 36.van der Spek AH, Fliers E, Boelen A. The classic pathways of thyroid hormone metabolism. Mol Cell Endocrinol. 2017;458: 29–38. doi: 10.1016/j.mce.2017.01.025 [DOI] [PubMed] [Google Scholar]
  • 37.van der Ven LTM, van de Kuil T, Verhoef A, Leonards PEG, Slob W, Cantón RF, et al. A 28-day oral dose toxicity study enhanced to detect endocrine effects of a purified technical pentabromodiphenyl ether (pentaBDE) mixture in Wistar rats. Toxicology. 2008;245: 109–22. doi: 10.1016/j.tox.2007.12.016 [DOI] [PubMed] [Google Scholar]
  • 38.Meerts IATM, Zanden JJ Van, Luijks EAC, Leeuwen-bol I Van, Jakobsson E, Bergman Å, et al. Potent competitive interactions of some brominated flame retardants and related compounds with human transthyretin in vitro. Toxicol Sci. 2000;56: 95–104. doi: 10.1093/toxsci/56.1.95 [DOI] [PubMed] [Google Scholar]
  • 39.Hamers T, Kamstra JH, Sonneveld E, Murk AJ, Kester MH a, Andersson PL, et al. In vitro profiling of the endocrine-disrupting potency of brominated flame retardants. Toxicol Sci. 2006;92: 157–73. doi: 10.1093/toxsci/kfj187 [DOI] [PubMed] [Google Scholar]
  • 40.Hamers T, Kamstra JH, Sonneveld E, Murk AJ, Visser TJ, Van Veizen MJM, et al. Biotransformation of brominated flame retardants into potentially endocrine-disrupting metabolites, with special attention to 2,2’,4,4’-tetrabromodipheyl ether (BDE-47). Mol Nutr Food Res. 2008;52: 284–298. doi: 10.1002/mnfr.200700104 [DOI] [PubMed] [Google Scholar]
  • 41.Noda S, Muroi T, Takakura S, Sakamoto S, Takatsuki M, Yamasaki K, et al. Preliminary evaluation of an in utero-lactation assay using 6-n-propyl-2-thiouracil. Arch Toxicol. 2005;79: 414–421. doi: 10.1007/s00204-004-0641-5 [DOI] [PubMed] [Google Scholar]
  • 42.Shibutani M, Woo GH, Fujimoto H, Saegusa Y, Takahashi M, Inoue K, et al. Assessment of developmental effects of hypothyroidism in rats from in utero and lactation exposure to anti-thyroid agents. Reprod Toxicol. 2009;28: 297–307. doi: 10.1016/j.reprotox.2009.04.011 [DOI] [PubMed] [Google Scholar]
  • 43.Spring SR, Bastian TW, Wang Y, Kosian P, Anderson GW, Gilbert ME. Thyroid hormone-dependent formation of a subcortical band heterotopia (SBH) in the neonatal brain is not exacerbated under conditions of low dietary iron (FeD). Neurotoxicol Teratol. 2016;56: 41–46. doi: 10.1016/j.ntt.2016.05.007 [DOI] [PubMed] [Google Scholar]
  • 44.O’Shaughnessy KL, Thomas SE, Spring SR, Ford JL, Ford RL, Gilbert ME. A transient window of hypothyroidism alters neural progenitor cells and results in abnormal brain development. Sci Rep. 2019;9: 1–6. doi: 10.1038/s41598-019-40249-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Ghassabian A, El Marroun H, Peeters RP, Jaddoe VW, Hofman A, Verhulst FC, et al. Downstream effects of maternal hypothyroxinemia in early pregnancy: nonverbal IQ and brain morphology in school-age children. J Clin Endocrinol Metab. 2014;99: 2383–2390. doi: 10.1210/jc.2013-4281 [DOI] [PubMed] [Google Scholar]
  • 46.Gyllenberg D, Sourander A, Surcel HM, Hinkka-Yli-Salomäki S, McKeague IW, Brown AS. Hypothyroxinemia during gestation and offspring schizophrenia in a national birth cohort. Biol Psychiatry. 2016;79: 962–970. doi: 10.1016/j.biopsych.2015.06.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Henrichs J, Bongers-Schokking JJ, Schenk JJ, Ghassabian A, Schmidt HG, Visser TJ, et al. Maternal thyroid function during early pregnancy and cognitive functioning in early childhood: the generation R study. J Clin Endocrinol Metab. 2010;95: 4227–4234. doi: 10.1210/jc.2010-0415 [DOI] [PubMed] [Google Scholar]
  • 48.Korevaar TIM, Muetzel R, Medici M, Chaker L, Jaddoe VWV, de Rijke YB, et al. Association of maternal thyroid function during early pregnancy with offspring IQ and brain morphology in childhood: a population-based prospective cohort study. Lancet Diabetes Endocrinol. 2016;4: 35–43. doi: 10.1016/S2213-8587(15)00327-7 [DOI] [PubMed] [Google Scholar]
  • 49.Modesto T, Tiemeier H, Peeters RP, Jaddoe V V., Hofman A, Verhulst FC, et al. Maternal mild thyroid hormone insufficiency in early pregnancy and attention-deficit/hyperactivity disorder symptoms in children. JAMA Pediatr. 2015;169: 838–845. doi: 10.1001/jamapediatrics.2015.0498 [DOI] [PubMed] [Google Scholar]
  • 50.Román GC, Ghassabian A, Bongers-Schokking JJ, Jaddoe VW V, Hofman A, De Rijke YB, et al. Association of gestational maternal hypothyroxinemia and increased autism risk. Ann Neurol. 2013;74: 733–742. doi: 10.1002/ana.23976 [DOI] [PubMed] [Google Scholar]
  • 51.Päkkilä F, Männistö T, Pouta A, Hartikainen AL, Ruokonen A, Surcel HM, et al. The impact of gestational thyroid hormone concentrations on ADHD symptoms of the child. J Clin Endocrinol Metab. 2014;99: 1–8. doi: 10.1210/jc.2013-2943 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Jamie C DeWitt

1 Jun 2022

PONE-D-22-07082Developmental exposure to the brominated flame retardant DE-71 reduces serum thyroid hormones in rats without hypothalamic-pituitary-thyroid axis activation or neurobehavioral changes in offspringPLOS ONE

Dear Dr. Ramhøj,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 16 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Jamie C. DeWitt

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf  and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following in the Funding Section of your manuscript:

“This study was funded by the Danish Environmental Protection Agency, Ministry of Environment and Food of Denmark. KS Hougaard received support from FFIKA, Focused Research Effort on Chemicals in the Working Environment, from the Danish Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

Please note that funding information should not appear in the Funding section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“This study was funded by the Danish Environmental Protection Agency, Ministry of Environment and Food of Denmark. KS Hougaard received support from FFIKA, Focused Research Effort on Chemicals in the Working Environment, from the Danish Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

4.  We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being

5. Please ensure that you refer to Figure 6 in your text as, if accepted, production will need this reference to link the reader to the figure

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

Reviewers have made several suggested modifications to the submitted manuscript for clarity and completeness. Please be sure to respond to all reviewer recommendations.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Minor editorial revisions will be needed.

1. Line 116: add St. Louis, MO, USA after Aldrich

2. Line 148: add company name, city, state, country after Tecniplast

3. Line 302: add comma before and after therefore

4. Lines 530-531, 542-543, 557-558, 574-575, 601-602, 615-617, 619-620, 653-654, 682, 686-687: titles should be small capitals

5. Line 535: Vitro should be vitro

6. Line 543 should be fixed appropriately

7. Line 568-569: Journal name should be appropriately abbreviated

8. Line 624: Heal should be Health

9. Line 637: pbfe should be PBDE

Reviewer #2: 1. Abstract, overall. The Abstract could be rewritten to use more precise language. As currently written, many parts are very general. For example, lines 38-40 do not indicate if this effect was in dams or offspring. Similarly, lines 40-41 indicate that no effects in brain function were observed by standard behavioral assays, but brain function is challenging to evaluate with just behavioral assays. Therefore, it is recommended that the Abstract be rewritten for precision.

2. Introduction (and in Discussion as well). It is suggested that the authors be more precise in the Introduction with respect to use of the term “marked.” It would improve the Introduction if the authors could include effect sizes/percent differences reported for these changes in levels of T4. By how much DE-71 reduces T4 would help readers understand the biological significance of this reported effect. This is done in line 84 and would be helpful if done throughout the Introduction.

3. Introduction, overall. It is recommended that the authors include a short paragraph in the Introduction about PBDEs in general and about DE-71 specifically. Why should this class of chemicals be studied for its developmental effects? What is its use? What is its environmental fate and transport? How are people exposed? What are human health concerns? This additional context would enhance the Introduction.

4. Methods, general. In the Introduction the authors indicate that one reason for undertaking the studies described in the manuscript was to determine if DE-71 affected the developing TH system similarly to TPO-inhibitors. However, it does not appear as if a TPO-inhibitor positive control was included as an experimental group. It is recommended that the authors provide data from such a group if it exists or include a brief statement of rationale about why such a group is not a necessary part of the experimental design.

5. Methods, line 150. Please indicate at what age were the one male and one female pup/litter weaned for Study 2.

6. Methods, lines 167-169. Please describe blood collections from pups on PD3 and PD8.

7. Methods, histopathology. Please provide more information on histopathological examinations, including whether a veterinary pathologist did the scoring, whether evaluators were blinded to dose groups, etc.

8. Methods, behavioral testing. It would be helpful if authors could include a brief statement of rationale for the behavioral tests chosen for their relevance to assessing impacts of TH on brain development.

9. Results, throughout. It is recommended that the authors provide context for terms such as “reduced,” i.e., by including percent differences or effect sizes.

10. Discussion, Table 1. This will make a nice addition to the literature on developmental neurotoxicity of PBDE.

11. Discussion, overall. The Discussion is very nicely put together.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Taisen Iguchi

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Jul 19;17(7):e0271614. doi: 10.1371/journal.pone.0271614.r002

Author response to Decision Letter 0


13 Jun 2022

Response to Reviewer’s Comments - PONE-D-22-07082

We thank the reviewers for their assessment of our manuscript and their insightful suggestions. We have responded to all comments below and amended the manuscript accordingly.

Reviewers' comments:

Academic editor: Reviewers have made several suggested modifications to the submitted manuscript for clarity and completeness. Please be sure to respond to all reviewer recommendations.

Thank you, we have revised the manuscript and believe that we have addressed all comments as detailed below and in the revised manuscript.

Reviewer #1: Minor editorial revisions will be needed.

Thank you for pointing out these errors and omissions. They are all now corrected in the revised manuscript.

1. Line 116: add St. Louis, MO, USA after Aldrich

2. Line 148: add company name, city, state, country after Tecniplast

3. Line 302: add comma before and after therefore

4. Lines 530-531, 542-543, 557-558, 574-575, 601-602, 615-617, 619-620, 653-654, 682, 686-687: titles should be small capitals

5. Line 535: Vitro should be vitro

6. Line 543 should be fixed appropriately

The citation has been updated and it follows PLOS ONE citation for websites.

7. Line 568-569: Journal name should be appropriately abbreviated

8. Line 624: Heal should be Health

Health is abbreviated to Heal in the PLOS ONE citation style.

9. Line 637: pbfe should be PBDE

Reviewer #2:

1. Abstract, overall. The Abstract could be rewritten to use more precise language. As currently written, many parts are very general. For example, lines 38-40 do not indicate if this effect was in dams or offspring. Similarly, lines 40-41 indicate that no effects in brain function were observed by standard behavioral assays, but brain function is challenging to evaluate with just behavioral assays. Therefore, it is recommended that the Abstract be rewritten for precision.

A1: We have revised the abstract to be more specific including in which animals effects were observed. We have also specified that our study concerns standard behavioral assays and, as the reviewer, we conclude that we lack more sensitive assays: “thus we propose that we lack assays to identify developmental neurotoxicity caused by chemicals disrupting the TH system through various mechanisms”.

2. Introduction (and in Discussion as well). It is suggested that the authors be more precise in the Introduction with respect to use of the term “marked.” It would improve the Introduction if the authors could include effect sizes/percent differences reported for these changes in levels of T4. By how much DE-71 reduces T4 would help readers understand the biological significance of this reported effect. This is done in line 84 and would be helpful if done throughout the Introduction.

A2: Thank you for this suggestion, we have specified the language and % reductions in the introduction.

3. Introduction, overall. It is recommended that the authors include a short paragraph in the Introduction about PBDEs in general and about DE-71 specifically. Why should this class of chemicals be studied for its developmental effects? What is its use? What is its environmental fate and transport? How are people exposed? What are human health concerns? This additional context would enhance the Introduction.

A3: We have added a paragraph in the introduction on this issue (lines 73-79): “Now banned, PBDEs were for decades used as flame retardants in both industrial and consumer products. Today, human exposure continues due to environmental contamination, persistence and bioaccumulation. Thus, the primary exposure routes are food and house dust [20]. DE-71 is a technical mixture of PBDEs and its congeners are still found in human serum, breast milk and house dust [20,21]. In humans and animals, exposure to PBDEs has been associated with a range of effects including neurotoxicity, disruption of the reproductive and thyroid hormone systems”

4. Methods, general. In the Introduction the authors indicate that one reason for undertaking the studies described in the manuscript was to determine if DE-71 affected the developing TH system similarly to TPO-inhibitors. However, it does not appear as if a TPO-inhibitor positive control was included as an experimental group. It is recommended that the authors provide data from such a group if it exists or include a brief statement of rationale about why such a group is not a necessary part of the experimental design.

A4: Thank you, we agree that it was a bit unclear and have added a sentence in the introduction line 105-107 to indicate that TPO-inhibitor induced effects serve as positive control: “The study design and endpoints are aligned with our previous studies of TPO inhibitors propylthiouracil, methimazole and amitrole [6,10] (refer to Table 1 for summary results). Also, the discussion elaborates on this issue.

5. Methods, line 150. Please indicate at what age were the one male and one female pup/litter weaned for Study 2.

A5: specified to PD27.

6. Methods, lines 167-169. Please describe blood collections from pups on PD3 and PD8.

A6: thank you, lines 174-175 specify that all blood samples are trunk blood. The following description pertains to ages, pooling and sex. We realize that the statement lines 165-166 were unclear and have rewritten the text so that it is now clearly stated that all blood collections are trunk blood. “In both studies all animals, as specified below, were killed by decapitation under CO2/O2 anesthesia and trunk blood collected”.

7. Methods, histopathology. Please provide more information on histopathological examinations, including whether a veterinary pathologist did the scoring, whether evaluators were blinded to dose groups, etc.

A7: On lines 215-217 we have added “All histological evaluations were performed by a veterinary pathologist and scoring was done blinded to exposure group.”

8. Methods, behavioral testing. It would be helpful if authors could include a brief statement of rationale for the behavioral tests chosen for their relevance to assessing impacts of TH on brain development.

A8: see A4

9. Results, throughout. It is recommended that the authors provide context for terms such as “reduced,” i.e., by including percent differences or effect sizes.

A9: Specification of effects sizes have been added to the results on pages 12-13.

10. Discussion, Table 1. This will make a nice addition to the literature on developmental neurotoxicity of PBDE.

A10: Thank you for this assessment.

11. Discussion, overall. The Discussion is very nicely put together.

A11: We thank the reviewer for the thoughtful comment.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Jamie C DeWitt

4 Jul 2022

Developmental exposure to the brominated flame retardant DE-71 reduces serum thyroid hormones in rats without hypothalamic-pituitary-thyroid axis activation or neurobehavioral changes in offspring

PONE-D-22-07082R1

Dear Dr. Ramhøj,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Jamie C. DeWitt

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Thank you for thoughtfully responding to reviewer concerns.

Reviewers' comments:

Acceptance letter

Jamie C DeWitt

7 Jul 2022

PONE-D-22-07082R1

Developmental exposure to the brominated flame retardant DE-71 reduces serum thyroid hormones in rats without hypothalamic-pituitary-thyroid axis activation or neurobehavioral changes in offspring

Dear Dr. Ramhøj:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Jamie C. DeWitt

Academic Editor

PLOS ONE


Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES